Novartis has updated its annual outlook, despite the market focusing on the disappointing result from Pluvicto. The company remains a top value stock for long-term investments, backed by M&A with a successful $2.1 billion venture with
Monte Rosa, causing its stock price to rise significantly. Despite slight dips,
Novartis is up 94% due to its Q3 beat. This beat came from strong sales from their key drugs, causing
Novartis to raise its outlook for 2024. Several investment firms have increased their holdings in
Novartis, signalling faith in the future performance. The company also made headlines with key victories and FDA approval of its drug
Scemblix.
Novartis is now positive about its sales targets and patent cliff, thereby increasing its guidance after Q3
earnings. Despite some challenges, analysts forecast strong price appreciation for
Novartis.
Novartis Stocks News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sat, 02 Nov 2024 09:47:09 GMT -
Rating 7
- Innovation 4
- Information 9
- Rumor -1
